Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Pharma-Bio Serv (PBSV) over the last 17 years, with Q4 2025 value amounting to $4399.0.

  • Pharma-Bio Serv's Share-based Compensation rose 3982.84% to $4399.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $35079.0, marking a year-over-year decrease of 2622.09%. This contributed to the annual value of $35079.0 for FY2025, which is 2622.09% down from last year.
  • Pharma-Bio Serv's Share-based Compensation amounted to $4399.0 in Q4 2025, which was up 3982.84% from $9999.0 recorded in Q3 2025.
  • In the past 5 years, Pharma-Bio Serv's Share-based Compensation ranged from a high of $28445.0 in Q4 2022 and a low of $684.0 during Q4 2023
  • In the last 5 years, Pharma-Bio Serv's Share-based Compensation had a median value of $14399.5 in 2022 and averaged $12779.6.
  • In the last 5 years, Pharma-Bio Serv's Share-based Compensation crashed by 9759.54% in 2023 and then soared by 35994.15% in 2024.
  • Over the past 5 years, Pharma-Bio Serv's Share-based Compensation (Quarter) stood at $21949.0 in 2021, then grew by 29.6% to $28445.0 in 2022, then crashed by 97.6% to $684.0 in 2023, then soared by 359.94% to $3146.0 in 2024, then surged by 39.83% to $4399.0 in 2025.
  • Its Share-based Compensation stands at $4399.0 for Q4 2025, versus $9999.0 for Q3 2025 and $10000.0 for Q2 2025.